Serotonin antagonists
AssigneeEli Lilly and Company
InventorsEdward E. Beedle, David W. Robertson, David T. Wong
Life of this patent
Estimating the term…
Abstract
This invention provides a method of selectively antagonizing the 5-HT.sub.1A receptor in mammals by administering aryloxypropanolamines. Novel aryloxypropanolamines are also claimed.
Claims10
A compound of Formula ##STR13## where m is 0-3, and Z.sub.c is (C.sub.7 -C.sub.8 cycloalkyl)--G--, C.sub.6 -C.sub.10 alkyl, phenyl substituted C.sub.2 -C.sub.10 alkyl, --(C.sub.1 -C.sub.4 alkylidene)--T--(C.sub.1 -C.sub.4 alkyl), or ##STR14## where each G is independently a bond or C.sub.1 -C.sub.4 alkylidene, a and c are independently 1-5, b is 0-5, and (a+c) is greater than 2, and T is --O--, --S--, --SO--, or --SO.sub.2 --, and pharmaceutically acceptable salts thereof.
The compound of claim 17 which is 1-(2-cyclopentylphenoxy)-3-(cycloheptylamino)-2-propanol or a pharmaceutically acceptable salt thereof.
The compound of claim 17 which is 1-(2-cyclopentylphenoxy)-3-(cyclooctylamino)-2-propanol or a pharmaceutically acceptable salt thereof.
The compound of claim 17 which is 1-(2-cyclopentylphenoxy)-3-(1,2,2-dimethylpropylamino)-2-propanol or a pharmaceutically acceptable salt thereof.
The compound of claim 17 which is 1-(2-cyclopentylphenoxy)-3-(1,1-dimethylbutylamino)-2-propanol or a pharmaceutically acceptable salt thereof.
The compound of claim 17 which is 1-(2-cyclopentylphenoxy)-3-(myrtanylamino)-2-propanol or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.